Clinical Trial Update: Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Glembatumumab Vedotin in combination with nivolumab and ipilimumab for advanced, unresectable solid tumors has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Triple-negative Breast Cancer
• Uveal Melanoma

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1, Phase 2 | Status: WITHDRAWN